943 related articles for article (PubMed ID: 23329400)
1. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
2. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
3. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.
Eissler N; Ruf P; Mysliwietz J; Lindhofer H; Mocikat R
Cancer Res; 2012 Aug; 72(16):3958-66. PubMed ID: 22745368
[TBL] [Abstract][Full Text] [Related]
4. Tumor-antigen-binding bispecific antibodies for cancer treatment.
Weidle UH; Kontermann RE; Brinkmann U
Semin Oncol; 2014 Oct; 41(5):653-60. PubMed ID: 25440609
[TBL] [Abstract][Full Text] [Related]
5. Influence of the bispecific antibody IgG subclass on T cell redirection.
Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
[TBL] [Abstract][Full Text] [Related]
6. Tumor antigen-dependent and tumor antigen-independent activation of antitumor activity in T cells by a bispecific antibody-modified tumor vaccine.
Fournier P; Schirrmacher V
Clin Dev Immunol; 2010; 2010():423781. PubMed ID: 21403859
[TBL] [Abstract][Full Text] [Related]
7. A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.
Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
Int J Cancer; 2006 Feb; 118(3):658-67. PubMed ID: 16108015
[TBL] [Abstract][Full Text] [Related]
8. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells.
Zeidler R; Mysliwietz J; Csánady M; Walz A; Ziegler I; Schmitt B; Wollenberg B; Lindhofer H
Br J Cancer; 2000 Jul; 83(2):261-6. PubMed ID: 10901380
[TBL] [Abstract][Full Text] [Related]
9. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
Aigner M; Janke M; Lulei M; Beckhove P; Fournier P; Schirrmacher V
Int J Oncol; 2008 Apr; 32(4):777-89. PubMed ID: 18360705
[TBL] [Abstract][Full Text] [Related]
10. Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine.
Fournier P; Aigner M; Schirrmacher V
Int J Oncol; 2010 Nov; 37(5):1203-17. PubMed ID: 20878068
[TBL] [Abstract][Full Text] [Related]
11. Bi-specific antibody therapy for the treatment of cancer.
Withoff S; Helfrich W; de Leij LF; Molema G
Curr Opin Mol Ther; 2001 Feb; 3(1):53-62. PubMed ID: 11249732
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
Lindhofer H; Menzel H; Günther W; Hültner L; Thierfelder S
Blood; 1996 Dec; 88(12):4651-8. PubMed ID: 8977258
[TBL] [Abstract][Full Text] [Related]
13. Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.
Cao Y; Axup JY; Ma JS; Wang RE; Choi S; Tardif V; Lim RK; Pugh HM; Lawson BR; Welzel G; Kazane SA; Sun Y; Tian F; Srinagesh S; Javahishvili T; Schultz PG; Kim CH
Angew Chem Int Ed Engl; 2015 Jun; 54(24):7022-7. PubMed ID: 25919418
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
[TBL] [Abstract][Full Text] [Related]
15. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
17. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
18. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.
Haas C; Schirrmacher V
Cancer Immunol Immunother; 1996 Nov; 43(3):190-4. PubMed ID: 9001573
[TBL] [Abstract][Full Text] [Related]
20. An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
Haas C; Herold-Mende C; Gerhards R; Schirrmacher V
Cancer Gene Ther; 1999; 6(3):254-62. PubMed ID: 10359211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
